share_log

Eli Lilly and Co | 10-Q: Q2 2024 Earnings Report

Eli Lilly and Co | 10-Q: Q2 2024 Earnings Report

禮來 | 10-Q:2024財年二季報
美股SEC公告 ·  08/08 23:34

牛牛AI助理已提取核心訊息

Eli Lilly and Co reported a significant increase in financial performance for the three and six months ended June 30, 2024. The company's revenue saw a substantial rise, with a 36% increase for the quarter, up from $11.3 billion in 2023 to $8.3 billion in 2024. Similarly, for the six-month period, revenue grew by 31%, from $20.1 billion in 2023 to $15.3 billion in 2024. Net income followed a similar trend, surging by 68% for both the quarter and six-month periods, reaching $3.0 billion and $5.2 billion respectively. Diluted earnings per share also saw a significant jump of 68% for the quarter, rising from $1.95 to $3.28, and a 67% increase for the six-month period, from $3.44 to $5.76. The growth in revenue and earnings was primarily attributed to increased sales of Mounjaro, Zepbound, and Verzenio, despite...Show More
Eli Lilly and Co reported a significant increase in financial performance for the three and six months ended June 30, 2024. The company's revenue saw a substantial rise, with a 36% increase for the quarter, up from $11.3 billion in 2023 to $8.3 billion in 2024. Similarly, for the six-month period, revenue grew by 31%, from $20.1 billion in 2023 to $15.3 billion in 2024. Net income followed a similar trend, surging by 68% for both the quarter and six-month periods, reaching $3.0 billion and $5.2 billion respectively. Diluted earnings per share also saw a significant jump of 68% for the quarter, rising from $1.95 to $3.28, and a 67% increase for the six-month period, from $3.44 to $5.76. The growth in revenue and earnings was primarily attributed to increased sales of Mounjaro, Zepbound, and Verzenio, despite declines in Trulicity and the sale of rights for Baqsimi. The company's net income and earnings per share benefited from a higher gross margin, although this was partially offset by increased expenses in research and development, asset impairment, restructuring, and other special charges, as well as marketing, selling, and administrative expenses. Eli Lilly's business development has been marked by the successful performance of its products in the market, particularly the newer offerings. The company's future plans and strategic initiatives, while not detailed in the announcement, are likely to continue focusing on innovation and market expansion to sustain growth.
2024年6月30日結束的三個月和六個月,禮來業績顯著增長。公司營業收入呈大幅上升趨勢,第二季度增長了36%,從2023年的113億美元增至2024年的83億美元。同樣,在六個月的時間裏,營業收入增長了31%,從2023年的201億美元增至2024年的153億美元。淨利潤也呈類似趨勢,第二季度和六個月的淨利潤激增了68%,分別達到30億美元和52億美元。攤薄每股收益也出現了顯着的飆升,第二季度增長了68%,從1.95美元升至3.28美元,六個月期間增長了67%,從3.44美元升至5.76美元。營收和收益的增長主要歸因於蒙加羅,澤帛和維傑尼歐銷售的增加,儘管Trulicity的銷售額下降,並出售...展開全部
2024年6月30日結束的三個月和六個月,禮來業績顯著增長。公司營業收入呈大幅上升趨勢,第二季度增長了36%,從2023年的113億美元增至2024年的83億美元。同樣,在六個月的時間裏,營業收入增長了31%,從2023年的201億美元增至2024年的153億美元。淨利潤也呈類似趨勢,第二季度和六個月的淨利潤激增了68%,分別達到30億美元和52億美元。攤薄每股收益也出現了顯着的飆升,第二季度增長了68%,從1.95美元升至3.28美元,六個月期間增長了67%,從3.44美元升至5.76美元。營收和收益的增長主要歸因於蒙加羅,澤帛和維傑尼歐銷售的增加,儘管Trulicity的銷售額下降,並出售Baqsimi的權利。公司淨利潤和每股收益受益於較高的毛利率,儘管這在一定程度上被研發,資產減值,重組和其他特別費用以及市場營銷,銷售和管理費用的增加所抵消。禮來的業務發展以市場產品的成功表現爲標誌,尤其是新產品的推出。雖然未在公告中詳細說明公司未來的計劃和戰略舉措,不過可能會繼續致力於創新和市場擴張以實現持續增長。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。